BMY Bristol Myers Squibb
Cliff is real but later and softer than feared; fairly priced with modest upside from replacement drugs.
The story
Bristol Myers Squibb is a mature large-cap pharma whose cash engines, Eliquis and Opdivo, face loss of exclusivity from 2028, while its growth portfolio (Camzyos, Reblozyl, Breyanzi, Cobenfy, the Opdualag and subcutaneous Opdivo franchises) has to fill the gap. The moat is its R&D and commercial scale, but each product's exclusivity runs out. The company is in harvest-and-replace mode: near-term revenue is holding up better than feared, the 2028-2030 cliff is unavoidable, and cost cuts are supporting margins.
I raised year-1 growth from -3% to 0%. TTM revenue reached $50.0B against $48.2B last fiscal year, so the legacy erosion is arriving later and the growth portfolio is ramping faster than my last take assumed. I nudged the target margin from 25% to 26% to match TTM margins after the cost program. It stays below peak because the post-LOE mix and Cobenfy launch spending cap it. I kept the other drivers: reinvestment through business development stays capital-heavy, and pharma beta stays below the market.
Value drivers
| Revenue growth (Y1) | 0.0% |
| Terminal growth | 1.5% |
| Forecast horizon | 7y |
| Target operating margin | 26.0% |
| Years to target margin | 5 |
| Sales-to-capital | 0.90 |
| Beta | 0.85 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 7.8% |
| Terminal WACC | 8.3% |
Valuation bridge
| PV of explicit FCFF | 50.49B |
| PV of terminal value | 82.20B |
| Equity value | 95.79B |
| ÷ shares → per share | $46.86 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 50.03B | 0.0% | 26.0% | 9.83B | 0 | 9.83B | 9.12B |
| 2 | 50.16B | 0.2% | 26.0% | 9.85B | 138.98M | 9.72B | 8.36B |
| 3 | 50.41B | 0.5% | 26.0% | 9.91B | 278.66M | 9.63B | 7.69B |
| 4 | 50.79B | 0.8% | 26.0% | 9.98B | 420.08M | 9.56B | 7.09B |
| 5 | 51.30B | 1.0% | 26.0% | 10.09B | 564.31M | 9.52B | 6.55B |
| 6 | 51.94B | 1.2% | 26.0% | 10.21B | 712.44M | 9.50B | 6.06B |
| 7 | 52.72B | 1.5% | 26.0% | 10.37B | 865.62M | 9.50B | 5.62B |
Key risks
- Eliquis and Opdivo erosion from 2028 is steeper than the growth portfolio can offset
- IRA Medicare price negotiation and MFN pricing pressure compress US margins
- Pipeline setbacks (Cobenfy adjunctive trials, cell therapy) push the company toward expensive acquisitions with net debt already near $35B
Catalysts
- Cobenfy label expansion and the uptake trajectory in schizophrenia and Alzheimer's psychosis
- Subcutaneous Opdivo conversion rates that extend the immuno-oncology franchise past the IV patent expiry